Drug Trial Radar · NCT07456891
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
650
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Jan 30, 2033
Study completion Jan 30, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.
Conditions
- Indication of the Parent Protocol
Interventions
RemibrutinibDrug
Remibrutinib film coated tablets in the respective dose strength of the parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with the occurrence of AEs or SAEsTime frame: throughout the study, approximately 7 years
Locations
46 sites in 9 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
Varna, Bulgaria · Recruiting
Novartis Investigative Site
Fredericton, New Brunswick, Canada · Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Québec, Quebec, Canada · Recruiting
Novartis Investigative Site
Verdun, Quebec, Canada · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Brno, Czechia · Recruiting
Novartis Investigative Site
Plzen Bolevec, Czechia · Recruiting
Novartis Investigative Site
Prague, Czechia · Recruiting
Novartis Investigative Site
Prague, Czechia · Recruiting
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Brest, France · Recruiting
Novartis Investigative Site
Montpellier, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Pierre-Bénite, France · Recruiting
Novartis Investigative Site
Rouen, France · Recruiting
Novartis Investigative Site
Saint-Mandé, France · Recruiting
Novartis Investigative Site
Gdansk, Poland · Recruiting
Novartis Investigative Site
Gdansk, Poland · Recruiting
Novartis Investigative Site
Poznan, Poland · Recruiting
Novartis Investigative Site
Krosno, Krosno, Poland · Recruiting
Novartis Investigative Site
Poznan, Poland, Poland · Recruiting
Novartis Investigative Site
Gwangju, South Korea · Recruiting
Novartis Investigative Site
Incheon, South Korea · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Daegu, Dalseo gu, South Korea · Recruiting
Novartis Investigative Site
Ansan, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Hwaseong-si, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Dongjak Gu, Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Novartis Investigative Site
Alicante, Spain · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Córdoba, Spain · Recruiting
Novartis Investigative Site
Las Palmas GC, Spain · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.